BioSpace News Archive

Predictive Oncology Inc. (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2021 and provided an update on business activities.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced new preclinical data from non-human primate (NHP) studies of 4D-150, a dual transgene, intravitreal gene therapy inhibiting four distinct VEGF family members for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

This week marks an important milestone as the first COVID-19 vaccine received emergency use authorization for children ages 12 to 15.

Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), today announced that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor

Orion Biotech Opportunities Corp. (the “Company”) today announced the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit.

StemExpress, a global leader in biomanufacturing, is rapidly expanding business operations throughout the nation.

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 3:40 p.m. ET.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration.